Myriad Genetics (MYGN) posted guidance for the full fiscal year ending June 30, 2010.
The Company expects revenue to be in the range of $360 million to $365 million, and earnings per diluted share to be in the range of $1.30 to $1.35.
Analyst were expecting both better revenue and EPS, and shares of Myriad are down about 26% today.
Comfort Systems USA (FIX) announced net income of $0.05 per diluted share, for the quarter ended March 31, as compared to net income of $0.18 per diluted share, in the first quarter of 2009.
The company posted revenues of $236.475 million in the current quarter, as compared to $280.274 million in 2009.
On the report, shares of Comfort Systems USA are down 15%.
Kronos Worldwide (KRO) posted net income for the first quarter of $42.8 million, or $.87 per diluted share, compared with a net loss of $26.6 million, or $.54 per diluted share, in the first quarter of 2009.
Net sales were $319.7 million in the first quarter.
Shares of Kronos are down about 8.8% following the report.
InterMune (ITMN) said the FDA has requested an additional clinical trial to support the efficacy of Esbriet in IPF patients. InterMune intends to meet with the FDA as soon as possible to explore the best ways to address the points raised by the agency and to discuss pathways to approval.
This morning InterMune was downgraded by Oppenheimer from outperform to perform and by Canaccord Adams from buy to hold.
InterMune shares are down 76%.
USEC (USU) reported a net loss of $9.7 million or 9 cents per share for the quarter ended March 31, compared to a net loss of $2.1 million or 2 cents per share for the first quarter of 2009.
On the wider loss, shares of USEC are down about 10.5%.
Any ideas and opinions presented in all Market News Video clips are for informational and educational purposes
only, and do not reflect the opinions of BNK Invest, Inc. or any of its affiliates, subsidiaries or partners.
In no way should any content contained herein be interpreted to represent trading or investment advice.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. Read Full Disclaimer.